Results 21 to 30 of about 49,464 (141)
Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review
Case Reports in Oncology, 2023 Chemotherapy is widely used in cancer treatment, and the drug Capecitabine is often used in treatment of breast cancer and usually well-tolerated. Toxicity from Capecitabine typically involves hand-foot syndrome, fatigue, nausea, reduced appetite, and ...
Miriam Hussein, Anders Bonde Jensen
doaj +1 more source
BMC Immunology, 2020 Background Early detection of capecitabine-resistance could largely increase overall survival of colorectal cancer (CRC) patients. Previous studies suggested examination of immune cells in peripheral blood would help to predict efficacy of chemotherapy ...
Yu Lu +9 more
doaj +1 more source
Life, 2021 Colorectal cancer (CRC) is a highly lethal malignant cancer. Capecitabine, a 5-fluororacil (5-FU) derivate, is its first-line drug, but the resistance of CRC to capecitabine is still the most challenging factor for curing patients.
Kuen-Lin Wu +5 more
doaj +1 more source
Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients
Saudi Pharmaceutical Journal, 2022 Background: Capecitabine is one of the fluoropyrimidine anticancer agents which is extensively used in the management of colorectal cancer. We have noticed a discrepancy between the doses we are using in our patients and the recommended dosing regimen ...
Saeed Alqahtani +5 more
doaj +1 more source
Cancer Communications, 2018 Background Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (
Giovanni Brandi +11 more
doaj +1 more source
Capecitabine-Associated Terminal Ileitis
Case Reports in Oncology, 2018 Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents.
Irene E.G. van Hellemond +2 more
doaj +1 more source
Effect of capecitabine on breast cancer patients with different estrogen receptor status
Bangladesh Journal of Pharmacology, 2020 This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status.
Gang Xu +5 more
doaj +1 more source
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. [PDF]
PLoS ONE, 2016 Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a meta ...
Ze-Chun Zhang +3 more
doaj +1 more source
Cancer Treatment and Research Communications, 2023 Background: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer.
L. Bender +6 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2019 Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking.
Femke M. de Man +10 more
doaj +1 more source